Technical Analysis for TTNP - Titan Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Calm After Storm | Range Contraction | -1.62% | |
| NR7 | Range Contraction | -1.62% | |
| Narrow Range Bar | Range Contraction | -1.62% | |
| Lower Bollinger Band Walk | Weakness | -1.62% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 7 hours ago |
| Down 2 % | about 7 hours ago |
| Down 1% | about 7 hours ago |
| Rose Above Lower Bollinger Band | 3 days ago |
| Down 1% | 3 days ago |
Get a Trading Assistant
- Earnings date: 02/28/2024
Titan Pharmaceuticals, Inc. Description
Titan Pharmaceuticals, Inc., a specialty pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. The company is developing Probuphine for the long term maintenance treatment of opioid dependence. Its Probuphine is designed to maintain a stable, around the clock blood level of the medicine buprenorphine in patients for six months following a single treatment; and utilizes ProNeura, a novel, proprietary, and long-term drug delivery technology. The company's ProNeura is also used in developing products for the treatment of other chronic conditions, such as Parkinson's disease. It is also developing Fanapt (iloperidone), an atypical antipsychotic for the treatment of schizophrenia. The company was founded in 1992 and is based in South San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Organic Compounds Chemical Compounds Parkinson's Disease Opioids Schizophrenia Drug Delivery Chronic Condition Morphinans Drug Delivery Technology Treatment Of Schizophrenia Antipsychotic Atypical Antipsychotics Drug Rehabilitation Buprenorphine Fanapt Iloperidone Psychopathology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.966 |
| 52 Week Low | 5.002 |
| Average Volume | 5,986 |
| 200-Day Moving Average | 7.30 |
| 50-Day Moving Average | 6.71 |
| 20-Day Moving Average | 6.55 |
| 10-Day Moving Average | 6.46 |
| Average True Range | 0.46 |
| RSI (14) | 33.33 |
| ADX | 18.41 |
| +DI | 20.35 |
| -DI | 36.98 |
| Chandelier Exit (Long, 3 ATRs) | 7.10 |
| Chandelier Exit (Short, 3 ATRs) | 6.80 |
| Upper Bollinger Bands | 7.63 |
| Lower Bollinger Band | 5.46 |
| Percent B (%b) | 0.01 |
| BandWidth | 33.18 |
| MACD Line | -0.23 |
| MACD Signal Line | -0.08 |
| MACD Histogram | -0.1588 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.71 | ||||
| Resistance 3 (R3) | 5.72 | 5.65 | 5.67 | ||
| Resistance 2 (R2) | 5.65 | 5.59 | 5.65 | 5.66 | |
| Resistance 1 (R1) | 5.57 | 5.55 | 5.53 | 5.56 | 5.65 |
| Pivot Point | 5.50 | 5.50 | 5.48 | 5.49 | 5.50 |
| Support 1 (S1) | 5.41 | 5.44 | 5.38 | 5.40 | 5.31 |
| Support 2 (S2) | 5.34 | 5.40 | 5.34 | 5.30 | |
| Support 3 (S3) | 5.26 | 5.34 | 5.29 | ||
| Support 4 (S4) | 5.25 |
